Avenue Therapeutics Announces Appointment of Joseph Vazzano as Vice President of Finance and Corporate Controller (principal financial and accounting officer) Aug 15, 2017
Fortress Biotech Forms New Subsidiary, Aevitas Therapeutics, Inc., to Develop Novel AAV Gene Therapy Treatments for Complement-Mediated Diseases Aug 14, 2017
Mustang Bio Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights Aug 14, 2017
Avenue Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights Aug 11, 2017
Fortress Biotech Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights Aug 09, 2017
Fortress Biotech Announces Filing of Provisional Patent Application for Caelum Biosciences’ CAEL-101 Jul 17, 2017
Fortress Biotech Announces Appointment of Lucy Lu, MD, as President and Chief Executive Officer of Subsidiary Avenue Therapeutics Jul 03, 2017
